Using market-exclusivity incentives to promote pharmaceutical innovation
Kesselheim, A.S.
New England Journal of Medicine 363(19): 1855-1862
2010
ISSN/ISBN: 0028-4793 PMID: 21047231 DOI: 10.1056/nejmhle1002961
Accession: 056815789
PDF emailed within 0-6 h: $19.90
Related References
Lietzan, E.; Acri née Lybecker, K.M.L. 2019: The innovation paradox: pharmaceutical marketing exclusivity and incentives for drug development Journal of Pharmaceutical Health Services Research 10(2): 169-175Yin, W. 2008: Market incentives and pharmaceutical innovation Journal of Health Economics 27(4): 1060-1077
Zhang, L.; Wang, J. 2021: Incentives to promote the US pharmaceutical innovation: empirical research based on the case of Epogen Drug Development and Industrial Pharmacy 2021: 1-14
Sinha, M.S.; Curfman, G.D.; Carrier, M.A. 2018: Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry JAMA 319(22): 2271-2272
Engelberg, A.B.; Kesselheim, A.S.; Avorn, J. 2009: Balancing innovation, access, and profits--market exclusivity for biologics New England Journal of Medicine 361(20): 1917-1919
Rome, B.N.; Kesselheim, A.S. 2020: Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 71(7): 1671-1675
Kraushaar, K.J. 1999: Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition Food and Drug Law Journal 54(2): 243-244
Kesselheim, A.S.; Rome, B.N.; Sarpatwari, A.; Avorn, J. 2017: Six-Month Market Exclusivity Extensions to Promote Research Offer Substantial Returns for many Drug Makers Health Affairs 36(2): 362-370
Morag-Sela, T.; Cohn, I.; Kowalski, T.J.; Jarecki-Black, J.; Clyde-Watson, Z. 2004: Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity Nature Biotechnology 22(12): 1591-1592
Lyles, A. 2006: Creating alternative incentives for pharmaceutical innovation Clinical Therapeutics 28(1): 126-128
Luft, H.S. 2009: Economic incentives to promote innovation in healthcare delivery Clinical Orthopaedics and Related Research 467(10): 2497-2505
Kesselheim, A.S. 2007: Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system Aaps Journal 9(3): E306-E311
González, P.; Macho-Stadler, I.és.; Pérez-Castrillo, D. 2016: Private versus social incentives for pharmaceutical innovation Journal of Health Economics 50: 286-297
Yousefi, N.; Mehralian, G.; Rasekh, H.R.; Tayeba, H. 2016: Pharmaceutical innovation and market share: evidence from a generic market International Journal of Pharmaceutical and Healthcare Marketing 10(4): 376-389
Conti, R.M.; Rosenthal, M.B. 2016: Pharmaceutical Policy Reform--Balancing Affordability with Incentives for Innovation New England Journal of Medicine 374(8): 703-706
Charles Bérubé; Marc Duhamel; Daniel Ershov 2012: Market Incentives for Business Innovation: Results from Canada Journal of Industry, Competition and Trade 12(1): 47-65
't Hoen, E.F.M.; Boulet, P.; Baker, B.K. 2017: Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation Journal of Pharmaceutical Policy and Practice 10: 19
Wickelgren, A.L. 2004: Innovation, market structure and the holdup problem: investment incentives and coordination International Journal of Industrial Organization 22(5): 693-713
Wesseling, J.H.; Niesten, E.M.M.I.; Faber, J.; Hekkert, M.P. 2013: Business Strategies of Incumbents in the Market for Electric Vehicles: Opportunities and Incentives for Sustainable Innovation Business Strategy and the Environment 24(6): 518-531
Dubois, P.; de Mouzon, O.; Scott‐Morton, F.; Seabright, P. 2015: Market size and pharmaceutical innovation The RAND Journal of Economics 46(4): 844-871